HOT stock here trading significantly below cash balance , FDA acceptance expected within days with potential FDA decision in Q3 this year . Stock has very strong insider and institutional ownership .This stock is a potential 10 bagger potential play because of its super low valuation .
Clearside BioMedical (CLSD)
Market Cap $39 Million Cash $65 Million Price 1.23
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.
If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.